Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancer

被引：91

作者：

Monk, BJ

Choi, DC

Pugmire, G

Burger, RA

机构：

[1] Univ Calif Irvine, Div Gynecol Oncol, Chao Family Comprehens Canc Ctr, Med Ctr, Orange, CA 92868 USA

[2] Kaiser Permanente, Div Med Oncol, Orange, CA 92801 USA

[3] Univ Calif Irvine, Dept Obstet & Gynecol, Orange, CA 92668 USA

来源：

GYNECOLOGIC ONCOLOGY | 2005年 / 96卷 / 03期

关键词：

bevacizumab; ovary; ovarian;

D O I：

10.1016/j.ygyno.2004.12.001

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background. Angiogenesis is pivotal in the development and progression of ovarian cancer and is an ideal candidate for novel treatment approaches. Case. A case of advanced, recurrent and refractory serous carcinoma is presented that responded to bevacizumab 15 mg/m(2) intravenously every 3 weeks after failing eleventh line cytotoxic chemotherapy and radiation. An objective durable response lasting at least 5 months was documented. Conclusion. Bevacizumab has activity in epitlielial ovarian carcinoma and larger scale trials are indicated. (c) 2004 Elsevier Inc. All rights reserved.

引用

页码：902 / 905

页数：4

共 9 条

[1] Angiogenesis in epithelian ovarian cancer [J].

Bamberger, ES ;

Perrett, CW .

JOURNAL OF CLINICAL PATHOLOGY-MOLECULAR PATHOLOGY, 2002, 55 (06) :348-359

[2]

DISAIA PJ, EPITHELIAL OVARIAN C, P289

[3] Evaluation of the antiangiogenic effect of Taxol in a human epithelial ovarian carcinoma cell line [J].

Hata, K ;

Osaki, M ;

Dhar, DK ;

Nakayama, K ;

Fujiwaki, R ;

Ito, H ;

Nagasue, N ;

Miyazaki, K .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2004, 53 (01) :68-74

[4] Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer [J].

Hurwitz, H ;

Fehrenbacher, L ;

Novotny, W ;

Cartwright, T ;

Hainsworth, J ;

Heim, W ;

Berlin, J ;

Baron, A ;

Griffing, S ;

Holmgren, E ;

Ferrara, N ;

Fyfe, G ;

Rogers, B ;

Ross, R ;

Kabbinavar, F .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (23) :2335-2342

[5] Cancer statistics, 2004 [J].

Jemal, A ;

Tiwari, RC ;

Murray, T ;

Ghafoor, A ;

Samuels, A ;

Ward, E ;

Feuer, EJ ;

Thun, MJ .

CA-A CANCER JOURNAL FOR CLINICIANS, 2004, 54 (01) :8-29

[6] Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer [J].

Johnson, DH ;

Fehrenbacher, L ;

Novotny, WF ;

Herbst, RS ;

Nemunaitis, JJ ;

Jablons, DM ;

Langer, CJ ;

DeVore, RF ;

Gaudreault, J ;

Damico, LA ;

Holmgren, E ;

Kabbinavar, F .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (11) :2184-2191

[7] Remaining controversies in the upfront management of advanced ovarian cancer [J].

Mano, MS ;

Awada, A ;

Minisini, A ;

Atalay, G ;

Lago, LD ;

Cardoso, F ;

Piccart, M .

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2004, 14 (05) :707-720

[8] Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study [J].

Ozols, RF ;

Bundy, BN ;

Greer, BE ;

Fowler, JM ;

Clarke-Pearson, D ;

Burger, RA ;

Mannel, RS ;

DeGeest, K ;

Hartenbach, EM ;

Baergen, R .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (17) :3194-3200

[9] A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer [J].

Yang, JC ;

Haworth, L ;

Sherry, RM ;

Hwu, P ;

Schwartzentruber, DJ ;

Topalian, SL ;

Steinberg, SM ;

Chen, HX ;

Rosenberg, SA .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (05) :427-434

← 1 →